Thomas Rupp

Managing Director at Axolabs Berlin GmbH

Speaker

Thomas is Managing Director of LGC Axolabs Berlin GmbH, a newly established CDMO for Pilot and Process scale manufacturing of oligonucleotides. Since mid 2013 he is also running Thomas Rupp Consulting as Managing Director and Principal, with a strong focus on synthetic RNA Therapeutics, specifically CMC, Technology assessment, Process development and optimization, and Facility design.
39 years ago, in 1985, he entered the world of synthetic nucleic acids in the research group of Nobel Laureate Prof. Harald zur Haussen at the German Cancer Research Center in Heidelberg, Germany, by setting-up the first core-facility for oligonucleotide synthesis and DNA sequencing in Europe. During this time, Thomas complimented his chemistry background with molecular biology and virology. Between 1990-1993 Thomas enjoyed working for Brian Sproat at EMBL, Heidelberg, developing a DNA synthesiser and a DNA sequencer, followed by a sabbatical year in Papillomavirus-related cancer research at Loyola University, Chicago, IL. In 1994 Thomas joined Innovir GmbH, Göttingen, Germany, developing manufacturing processes for synthetic RNA Therapeutics, namely Ribozymes and successively moved 1997 to Berlin, Germany to setup the Spiegelmer production lab at Noxxon Pharma AG.
In 2002 he accepted a position as Field Application Specialist for oligonucleotide related products at GEHC with main responsibilities in Asia and Europe. Between 2010 and 2013 he worked as Technical Consultant for Girindus, Cincinnati, USA.